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ABSTRACT
Adult T cell leukemia/lymphoma (ATL) is a highly aggressive T cell malignancy, and has a poor prognosis. Re-
cently, allogeneic-hematopoietic stem cell transplantation (allo-HSCT) has been suggested to improve the out-
come. We retrospectively analyzed 15 patients with ATL who had received allo-HSCT in 2 institutions in
Hokkaido, Japan. The median age of the patients was 57 years. The estimated 3-year overall survival (OS) and
progression-free survival (PFS) rates were 73.3% and 66.7%, respectively. Calcineurin inhibitor dosage was re-
duced and administration was discontinued abruptly in 6 of the 15 patients for disease control; as a result, 4
(66.7%) of the 6 patients achieved complete response (CR) or partial response. Therefore, a graft-versus-leuke-
mia/lymphoma (GVL) effect might be induced by discontinuation of immunosuppression. Thirteen of the 15 pa-
tients were followed up by monitoring HTLV-1 proviral DNA levels. In 10 of the 11 patients with positive
HTLV-1 proviral DNA before allo-HSCT, HTLV-1 proviral DNA became undetectable at least once after
allo-HSCT, and only 1 of the 5 patients in whom HTLV-1 proviral DNA became detectable after allo-HSCT
relapsed. Compared to the results of past studies, these results show that allo-HSCT greatly improved the prog-
nosis of ATL and suggest a contribution of the induction of a GVL effect.
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AdultT-cell leukemia/lymphoma (ATL) is a highly
aggressive T cell malignancy associated with infection
of a retrovirus, humanT cell lymphotropic virus type 1
(HTLV-1) [1-4]. Acute and lymphoma types of ATL
have a particularly poor prognosis because of resis-
tance to conventional chemotherapy or high-dose che-motherapy at an early stage during its clinical course.
The median survival periods for patients with these
subtypes of ATL who have received chemotherapy
are 3 to 13 months [5-8].
Successful allogeneic-hematopoietic stem cell
transplantation (allo-HSCT) has recently been re-
ported, and several groups have reported encouraging817
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mia/lymphoma (GVL) effect has also been suggested
to improve treatment outcomes.
We retrospectively analyzed 15 patients with ATL
who had received allo-HSCT in the Hokkaido Uni-
versity Hospital and the Sapporo Hokuyu Hospital.
Compared to results of past studies, our results more
strongly suggest that allo-HSCT improves the out-
come for ATL, and that a GVL effect improves the
clinical outcome after allo-HSCT.
PATIENTS AND METHODS
Diagnosis and Classification of clinical Subtypes of
ATL
In all cases, the diagnosis of ATL was based on
clinical features, immunophenotype, presence of
anti-HTLV-1 antibody, and clonal integration of
HTLV-1 proviral DNA. Clinical subtypes of ATL
were classified according to the criteria of the Japanese
Lymphoma Study Group [9].
Response to Treatment
The response criteria were defined as follows [5]:
complete response (CR, resolution of all malignant
disease for 4 weeks or more); partial remission (PR, re-
duction in measurable indices lasting 4 weeks or more,
without the development of new lesions or disease
progression); and progressive disease (PD, increase in
measurable disease or in the number of circulating
leukemic cells by 25% or more).
Patients’ Characteristics
Fifteen patients with ATL (acute-type, n5 6; lym-
phoma-type, n5 8; chronic-type, n5 1) received allo-
HSCT at the Hokkaido University Hospital and the
Sapporo Hokuyu Hospital between 2000 and 2007.
These hospitals are located in Hokkaido, an area of
Japan in which there is a small number of HTLV-1 in-
fection cases compared to the number of cases in the
Shikoku or Kyushu districts of Japan. The patient
with chronic type of ATL received allo-HSCT be-
cause of poor disease control and the existence of an
appropriate HLA-identical sibling donor.
Clinical characteristics of the ATL patients are
shown in Tables 1 and 2. The median age at the time
of diagnosis was 57 years (range: 41-66 years). Disease
statuses at SCT were CR in 9 patients (molecular CR
in 1 patient), PR in 5 patients, and PD in 1 patient.
Eight patients received stem cells from bone marrow
(BM), 4 patients received stem cells from peripheral
blood (PB), and 3 patients received stem cells from
BM and PB. Ten patients underwent transplantation
from HLA-identical siblings, 2 donors having anti-
HTLV-1 antibodies, and 5 patients underwent trans-
plantation from unrelated HLA-identical donors.Preconditioning Regimens and Graft-versus-Host
Disease (GVHD) Prophylaxis
Five patients received a conventional regimen (eto-
poside1 cyclophosphamide [Cy]1 total-body irradia-
tion [TBI]), and 10 patients received a reduced-intensity
(RIC) regimen (fludarabine [Flu] 1 busulphan [Bu] 6
TBI for 5 patients and Flu 1 melphalan 6 TBI for 5
patients). GVHD prophylaxis consisted of treatment
with cyclosporine (CsA) or tacrolimus (FK) and short-
term methotrexate (sMTX): CsA 1 sMTX in 11
patients and FK1 sMTX in 4 patients (Table 2).
Measurement of HTLV-1 Proviral DNA
HTLV-1 proviral DNAwasmeasured inmononu-
clear cells of PB or BM before and after allo-HSCT by
Southern blot hybridization, dot blot qualitative anal-
ysis using polymerase chain reaction (PCR) amplifica-
tion of the HTLV-1 pX gene and gag gene, and
quantitative real-time PCR amplification of HTLV-
1 tax gene, according to the recommendations of the
manufacture’s (SRL, Inc. and Mitsubishi Chemical
Medience Corporation). The quantitative real-time
PCR method has been previously described [10].
Statistical Analysis
Overall survival (OS) and progression-free survival
(PFS) were analyzed according to the method of
Kaplan and Meier. OS was calculated from the day
of allo-HSCT until death or last-follow up, and PFS
was calculated until disease progression, death, or
last follow-up.
RESULTS
Engraftment
All patients tolerated the conditioning regimen
and achieved neutrophil recovery (0.5  104/mL) at
a median of 17 days (range: 14-20 days) (Table 3),
and 13 of the 15 patients achieved platelet recovery ex-
ceeding 5.0  104/mL at a median of 29 days (range:
14-46 days).
GVHD
Acute GVHD (aGVHD) developed in 8 (53.3%)
of the 15 patients: grade I GVHD in 1 patient, grade
II in 5 patients and grade III in 2 patients. Chronic
GVHD (cGVHD) developed in 10 (76.9%) of 13 pa-
tients followed up over 100 days from transplantation,
with limited disease in 3 patients and extensive disease
in 7 patients (Table 3). Two patients developed grade
III aGVHD after reduction in the dose of and abrupt
discontinuation of administration of a calcineurin in-
hibitor for induction of aGV-ATLeffect, and 1 patient
(Case 6) also developed severe cGVHDafter discontin-
uation of the immunosuppression.
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Age/Sex Subtype
WBC (/mL)
(Abnormal Lymphocyte(/mL)) LDH(IU/L)
Organ
Involvement Induction Therapy
Case 1 41/F Acute 27,300 (18,837) NA Skin mNLG-2
Case 2 44/M Acute 331,000 (304,520) 1611 Liver CHOP-V-MMV
Case 3 46/F Chronic 10,900 (0) 245 Skin PUVA1DCF
Case 4 47/F Lymphoma 2500 (0) 340 — CHOP-E
Case 5 49/F Lymphoma 20,500 (820) 603 Spleen CHOP/VCAP/AMP/VECP
Case 6 53/F Lymphoma 6800 (0) 326 — DCF/CHOP
Case 7 56/F Lymphoma 5100 (0) 558 — VCAP/AMP/VECP
Case 8 57/F Lymphoma 9430 (0) 165 Gl tract VCAP/AMP/VECP
Case 9 58/M Lymphoma 8050 (0) 208 — CHOP/VCAP/AMP/VECP
Case 10 60/F Acute 17,800 (8188) 290 Spleen VCAP/AMP/VECP
Case 11 60/F Lymphoma NA (12,000) 593 — VCAP/AMP/VECP
Case 12 61/F Lymphoma 5000 (115) 363 — CHOP
Case 13 62/F Acute 39,200 (10,976) 1216 Liver, Skin VEPA
Case 14 64/F Acute 15,840 (5544) 418 — VCAP/AMP/VECP
Case 15 66/M Acute 26,000 (13,780) 595 Liver, Skin, PE VCAP/AMP/VECP
Gl tract indicates gastrointestinal tract; PE, pleural effusion; mNLG-2, cyclophosphamide, adriamycin, vincristine prednisolone, tetrahydropyr-
anyl adriamycin, ranimustine, vindesine, etoposide, carboplatin; CHOP-V-MMV, cyclophosphamide doxorubicin, vincristine, prednisolone,
etoposide, vindesine, ranimustine, mitoxantrone; PUVA, psoralen and ultraviolet light; DCF, deoxycoformycin; CHOP, cyclophosphamide,
doxorubicin, vincristine, prednisolone; VCAP, vincristine, adriamycin cyclophosphamide, prednisolone; AMP, adriamycin, ranimustine,
prednisolone; VECP, vindesine, etoposide, carboplatin prednisolone; VEPA, vincristine, cyclophosphamide, prednisolone, doxorubicin.Induction of a GVL Effect
A calcineurin inhibitor dose was reduced and ad-
ministration was abruptly discontinued in 6 of the 15
patients for induction of a GVL effect because of re-
lapse, regrowth of residual disease, remaining ATLL
cells, or remaining recipient-type cells in chimerism
analysis. As a result, 3 patients (Cases 2, 7, and 13)
achieved CR, 1 patient (Case 10) achieved PR, and 2
patients (Cases 5 and 8) had PD. However, 2 of the
3 patients who achieved CR developed grade III
aGVHD and 1 of the 3 patients developed lung
cGVHD for which mechanical ventilation was tempo-
rarily needed.Survival, Relapse (or Disease Progression), and
Treatment-Related Mortality (TRM)
The median follow-up period after transplanta-
tion was 35.5 months (range: 1.5-86.0 months) and
the median PFS period after transplantation was
35.5 months (range: 0.4-86.0 months). The estimated
3-year OS and PFS rates were 73.3% and 66.7%, re-
spectively (Figure 1). Four of the 5 patients who re-
ceived CST are alive and 1 patient (Case 5) died of
relapse 477 days after transplantation. Seven of the
10 patients who received RIST are alive. One patient
(Case 8) died of disease progression 45 days after
transplantation, and 2 patients (Cases 9 and 15)Table 2. Transplant characteristics
Time from Diagnosis
to SCT(Days)
Disease
Status Donor
Stem Cell
Source
Conditioning
Regimen GVHD Prophylaxis
Case 1 150 CR Related BM1PB VP-161Cy1TBI CsA1sMTX
Case 2 215 PR Related BM VP-161Cy1TBI CsA1sMTX
Case 3 825 PR Related BM VP-161Cy1TBI CsA1sMTX
Case 4 150 CR Related BM1PB VP-161Cy1TBI CsA1sMTX
Case 5 425 PR Unrelated BM VP-161Cy1TBI FK1sMTX
Case 6 1275 CR Unrelated BM Flu1L-PAM1TBI FK1sMTX
Case 7 680 PR Unrelated BM Flu1BU1TBI CsA1sMTX
Case 8 153 PD Related BM Flu1BU1TBI CsA1sMTX
Case 9 196 CR Related PB Flu1L-PAM CsA1sMTX
Case 10 157 CR Unrelated BM Flu1BU1TBI FK1sMTX
Case 11 232 PR Related (HTLV-1(1)) PB Flu1L-PAM CsA1sMTX
Case 12 371 CR Related BM1PB Flu1L-PAM CsA1sMTX
Case 13 140 CR Related PB Flu1BU CsA1sMTX
Case 14 297 CR Unrelated BM Flu1BU1TBI FK1sMTX
Case 15 127 CR Related (HTLV-1(1)) PB Flu1L-PAM CsA1sMTX
VP-16 indicates etoposide; Cy, cyclophosphamide; TBI, total body irradiation; Flu, fludarabine; L-PAM, melphalan; BU, busulfan; CsA,
cyclosporine; FK, tacrolomus; sMTX, short-term methotrexate.
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Engraftment (Day)
Neutrophil/Platelet
aGVHD
(Day/Grade)
aGVHD
(Day/Type) Outcome Cause of Death
Follow-up
Time (Month)
Case 1 18/46 None 120/Extensive CR Alive 79.01
Case 2 15/24 31/? 351/Extensive CR(after d/c CI) Alive 61.71
Case 3 16/26 57/? 365/Extensive CR Alive 69.11
Case 4 17/29 26/? 252/Limited CR Alive 86.01
Case 5 15/27 26/? 160/Limited Dead, d477 Relapse 16.0
Case 6 17/26 None None CR Alive 37.01
Case 7 14/29 None None CR (complete chimera
after reducing CI)
Alive 45.31
Case 8 16/24 8/? Not evaluable Dead, d45 Disease
progression
1.5
Case 9 14/33 None None Dead, d296 TTP 9.7
Case 10 17/30 69/? 210/Extensive LN relapse,d192
(PR after d/c CI)
Alive 21.21
Case 11 20/- None 142/Extensive CR Alive 35.51
Case 12 16/26 None 132/Extensive CR Alive 31.01
Case 13 16/14 29/? 69/Extensive CR (complete chimera
after d/c CI)
Alive 58.91
Case 14 16/31 None 80/Limited CR Alive 4.61
Case 15 19/- 17/? Not evaluable Dead, day46 Bacterial
pneumonia
1.5
CI indicates calcineurin inhibitor; TTP, thrombotic thrombocytopenic purpura.died of TRM because of allo-SCT-related throm-
botic thrombocytopenic purpura (TTP) and bacterial
pneumonia (Table 3). In 2 patients whose donors had
anti-HTLV-1 antibodies, 1 patient (Case 11) is alive
and has achieved CR (with negative HTLV-1 provi-
ral DNA), and the other patient (Case 15) died of
TRM.
Also, none of the patients were treated with antire-
troviral agents after HSCT.
Clinical Course of HTLV-1 Proviral DNA
Thirteen of the 15 patients were followed up by
monitoring HTLV-1 proviral DNA levels before and
after allo-HSCT (Figure 2). In 10 of the 11 patients
with positive HTLV-1 proviral DNA before allo-
HSCT, HTLV-1 proviral DNA became undetectablemore than 1 time after allo-HSCT. (One patient [Case
1] was followed up in another hospital, so the last day
for data of HTLV-1 proviral DNA was day 120, and
was positive by dot blot qualitative analysis using
PCR amplification of the HTLV-1 gag gene.) Al-
though HTLV-1 proviral DNA became detectable in
5 patients again (Cases 4, 5, 7, 10, and 13), 1 of those
patients (Case 5) relapsed with leukemia 6 months af-
ter allo-HSCT. Case 10 also relapsed in lymph nodes
but remained in CR in peripheral blood and bone mar-
row at that time. In 2 patients with negative HTLV-1
proviral DNA by Southern blot hybridization before
allo-HSCT, 1 patient (Case 9) died of TRM and 1 pa-
tient (Case 11) is alive, and the status of HTLV-1 pro-
viral DNA remained undetectable in both of those
patients.Figure 1. Kaplan-Meier plot of OS and PFS following allogeneic stem cell transplantation for ATL.
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Figure 2. Transition of HTLV-1 proviral DNA before and after allo-HSCT (open squares: negative results, closed squares: positive results).DISCUSSION
ATL is a highly aggressive hematologic malig-
nancy, and its prognosis is poor because ATL cells
are resistant to chemotherapy at an early stage. Cases
of treatment with allo-HSCThave been reported since
1987 [11], and since the report of Utsunomiya et al. in
2001 [12], results of several retrospective analyses and
a phase I clinical trial of allo-HSCT for ATL have
been reported in Japan [13-17]. Survival periods of pa-
tients in those studies ranged from 33.3% to 60% for
OS and from 20% to 64% for TRM. In our retrospec-
tive analysis, 3-year OS was 73.3%, 3-year PFS was
66.7%, and TRM was 20%. These results of allo-
HSCT with ATL are much better than those of past
studies. Disease progression occurred in only 2 pa-
tients (13.3%) after allo-HSCT in this study. The
background of this outcome is considered to be that
there was only 1 patient with PD before allo-HSCT
and better disease control by the induction chemother-
apy was obtained in many cases, although these were
not greatly different from those in past studies. Also,
regarding the lower TRM rate, there was not a great
difference in GVHD prophylaxis compared to that inpast studies, and special treatment of infection was
not done compared to other hematologic malignancies
in our hospital. As mentioned above, this study was
carried out in Hokkaido, an area of Japan in which
there is a small number of HTLV-1 infection cases,
and past studies were carried out in Kyushu and Shi-
koku, areas in which HTLV-1 infection is endemic.
Some studies have shown several subtypes of HTLV-
1 provirus, and the significance of these subtypes in
oncogenesis of ATL has been suggested [18-22]. Al-
though this study was a retrospective analysis and we
could not investigate the subtypes of HTLV-1 provi-
rus, 1 reason for the good outcome in this study might
be related to the difference in subtypes of ATL. Fur-
ther studies are needed to clarify the relationship be-
tween subtypes of HTLV-1 provirus and prognosis
of ATL.
Another reason might be the induction of a GVL
effect by reducing the dose of and abrupt discontinua-
tion of administration of a calcineurin inhibitor. A re-
lationship between GVHD and GVL effect has been
reported in acute lymphoblastic leukemia (ALL)
[23,24]. In ATL, there have also been some reports
822 S. Shiratori et al.about the efficacy of abrupt discontinuation of immu-
nosuppression for a GVL effect [25-27], and the gen-
eration of cytotoxic T lymphocytes against some
epitopes of ATL cells might be induced [28-30]. In
our study, 4 (66.7%) of the 6 patients in whom the
dose of a calcineurin inhibitor was reduced and admin-
istration was abruptly discontinued achieved CR or
PR, suggesting that these are effective for induction
of a GVL effect. However, discontinuation of the ad-
ministration of a calcineurin inhibitor was not effective
for 2 patients (Cases 5 and 8) in whom disease progres-
sion developed rapidly after allo-HSCT. Thus, it is
thought that a GVL effect induced by abrupt discon-
tinuation of immunosuppression may not be sufficient
for disease control at the stage of aggressive disease
progression. It is possible that the magnitude of
a GVL effect varies with the individual, but this is
not clear in the present study. Further studies are
needed to clarify the mechanism of a GVL effect. On
the other hand, most of the cases in which disease con-
trol was achieved by abrupt discontinuation of admin-
istration of a calcineurin inhibitor developed severe
GVHD, suggesting that a balance between GVHD
and GVL effect is a critical point in clinical manage-
ment. However, immunosuppression (calcineurin in-
hibitor and/or steroid) was restarted in all cases with
severe GVHD. Because no cases showed regrowth of
ATL or reappearance of recipient-type cells in chime-
rism analysis for the restart of immunosuppression,
a GVL effect induced by abrupt discontinuation of cal-
cineurin inhibitor may continue for a long time even
after the restart of immunosuppression.
In this study, HTLV-1 proviral DNA became
undetectable more than 1 time after allo-HSCT in
all patients with positive HTLV-1 proviral DNA
before allo-HSCT. However, in 5 patients, HTLV-
1 proviral DNA became detectable again, and only 1
patient relapsed. Because complete chimerism was
maintained in peripheral blood in the other 4 patients,
donor-derived cells appeared to be infected with
HTLV-1 in the host after allo-HSCT according to
the results of a past study [31]. Further studies are
needed to clarify the association between relapse and
reappearance of HTLV-1 proviral DNA after allo-
HSCT.
The risk factors before allo-HSCT, particularly
the disease status in allo-HSCT for ATL, are still un-
clear. In this study, the patient who had PD before
allo-HSCT developed disease progression at an early
stage after allo-HSCT. On the other hand, in the pa-
tients who had been in PR before allo-HSCT, only
1 patient relapsed after allo-HSCT and the other 4
patients have been in CR, an outcome that is not in-
ferior to the outcome of patients who had been in CR
before allo-HSCT. Further studies are needed to es-
tablish the of risk classification in allo-HSCT with
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